Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31343271 | 1.00 | LOXL2 (0.54) | LOXL2ALDH1A1HPGDMAPTTSHR | |
| Hydrochloric Acid SCHEMBL30933600 | 0.98 | LOXL2 (0.53) | LOXL2ALDH1A1HPGDMAPTTSHR | |
| Hydrochloric Acid SCHEMBL9931554 | 0.98 | LOXL2 (0.53) | LOXL2ALDH1A1HPGDMAPTTSHR | |
| Hydrochloric Acid SCHEMBL25290200 | 0.91 | CYP4F2 (0.62) | LOXL2ALDH1A1HPGDMAPTTSHR | |
| SCHEMBL1827959 | 0.87 | LOXL2 (0.54) | LOXL2ALDH1A1HPGDMAPTTSHR | |
| SCHEMBL12332820 | 0.86 | CYP4F2 (0.58) | ALDH1A1HPGDMAPTTSHRGAA | |
| SCHEMBL1671454 | 0.84 | CYP4F2 (0.73) | ALDH1A1TSHRHSD17B10CYP4F2CYP4A11 | |
| SCHEMBL13066708 | 0.83 | CYP4F2 (0.51) | ALDH1A1HPGDMAPTTSHRGAA | |
| SCHEMBL844331 | 0.83 | CYP4F2 (0.72) | ALDH1A1HPGDMAPTTSHRGAA | |
| SCHEMBL30750476 | 0.83 | CYP4F2 (0.72) | ALDH1A1HPGDMAPTTSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A (CH) | 2019-08-27 | — | — | US | disclosed |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2018-07-19 | — | — | US | disclosed |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2018-07-19 | — | — | US | disclosed |
| US-9949955-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949955-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-26 | — | — | US | disclosed |
| WO-2014167444-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-10-16 | — | — | WO | disclosed |
| EP-2718284-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013118071-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | WO | disclosed |
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2013072825-A1 | PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013038308-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | LOXL2 1350/4885ALDH1A1 163/4885HPGD 9/4885 |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | LOXL2 1599/4885ALDH1A1 170/4885HPGD 9/4885 |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | PTGES, PTGS1, PTGIS | LOXL2 1599/4885ALDH1A1 170/4885HPGD 9/4885 |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | LOXL2 1599/4885ALDH1A1 170/4885HPGD 9/4885 |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | LOXL2 1599/4885ALDH1A1 170/4885HPGD 9/4885 |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | PTGES, PTGS1, PTGIS | LOXL2 1599/4885ALDH1A1 170/4885HPGD 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.